Gilead to Buy German Biotech Tubulis for $3 Billion
Digest more
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for ...
While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...
In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...
The news is the latest example of the biotech industry's struggles in the Bay Area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results